I'm Interested

Study: Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)

Please select your preferred method of contact
Not every study team can send text messages. If they can’t text message, they will reach out by phone.

Thank you for expressing your interest in a research study and for taking the time to provide your information.

By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 5 to 7 business days.

Please understand that:

  • The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does not enroll you into the study, or guarantee that you qualify for the study.
  • It is always your choice to participate.

Thanks again. Volunteers such as yourself are at the core of our work.